Trial Profile
A Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin With or Without Donor Lymphocyte Infusion in Patients With Advanced Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2016 New trial record
- 16 May 2016 Results published in the Bone Marrow Transplantation